Publications by authors named "A Chiappori"
Article Synopsis
- This study investigates gene expression differences in Small Cell Lung Cancer (SCLC) to find potential biomarkers that could enhance clinical testing and treatment options.
- Researchers used RNA expression profiling on tumor samples from SCLC patients and found a strong correlation between their methods and traditional sequencing techniques, revealing varying gene expressions between primary and metastatic sites.
- The findings suggest that profiling SCLC at a clinical level can aid in identifying specific subtypes, which could be crucial for designing more effective clinical trials and targeted therapies for patients.
Background: Plinabulin is a GEF-H1 releasing agent with an immune-enhancing function. We report results from a multicenter Phase I/II study (NCT03575793) assessing plinabulin in combination with nivolumab and ipilimumab for the treatment of recurrent SCLC.
Methods: In Phase I, patients were enrolled using a 3 + 3 design to determine dose-limiting toxicities (DLTs) and recommended Phase 2 dose (RP2D).
Background: The optimal treatment sequencing for patients with metastatic epidermal growth factor receptor ()-mutant non-small cell lung cancer (NSCLC) remains a subject of debate. In the United States, osimertinib is the preferred tyrosine kinase inhibitor (TKI) in the first-line setting. However, small retrospective studies suggest that alternative TKI sequencing strategies may produce similar outcomes.
View Article and Find Full Text PDFArticle Synopsis
- The study investigated the effectiveness of combining ramucirumab with nivolumab as a second-line treatment for patients with unresectable mesothelioma, aiming to improve the objective response rate (ORR) compared to nivolumab alone.
- A total of 34 patients were treated, showing an overall ORR of 22.6%, with a higher ORR of 43% in patients with nonepithelioid tumor histology.
- While the study found the combination to be safe with manageable side effects, it did not meet the primary goal of a 40% ORR, suggesting that further research is needed, particularly for patients with nonepithelioid tumors.
Background: Activating mutations in EGFR or KRAS are highly prevalent in NSCLC, share activation of the MAPK pathway and may be amenable to combination therapy to prevent negative feedback activation.
Methods: In this phase 1/1B trial, we tested the combination of binimetinib and erlotinib in patients with advanced NSCLC with at least 1 prior line of treatment (unless with activating EGFR mutation which could be treatment-naïve). A subsequent phase 1B expansion accrued patients with either EGFR- or KRAS-mutation using the recommended phase 2 dose (RP2D) from Phase 1.